1. Impact of preoperative antiviral therapy on the prognosis of hepatitis B virus-related hepatocellular carcinoma
- Author
-
Yuxin Liang, Deyuan Zhong, Zilong Zhang, Yuhao Su, Su Yan, Chunyou Lai, Yutong Yao, Ying Shi, Xiaolun Huang, and Jin Shang
- Subjects
Anti-PD-1 therapy ,HCC ,Curative resection ,Recurrence ,Survival ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background For chronic hepatitis B virus (HBV) infection patients, increasing evidence has demonstrated the effectiveness of expanding the indications and applicable population for antiviral therapy. However, the expanded indication of antiviral therapy for hepatocellular carcinoma (HCC) remains to be further explored. Methods 196 HBV-related HCC patients who received radical hepatectomy and nucleos(t)ide analogues (NAs) therapy at Sichuan Provincial People’s Hospital were enrolled in this study. HCC recurrence, overall survival (OS), early virological (VR) and biochemical responses (BR) of patients were compared between different NAs therapy and the use of anti-programmed cell death protein 1 (PD-1) therapy. Results NAs therapy at different timing of surgery was a strong independent risk factor for postoperative recurrence and overall mortality of HBV-related HCC patients. Furthermore, in HCC patients who received postoperative anti-PD-1 therapy, patients with HBV DNA
- Published
- 2024
- Full Text
- View/download PDF